Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 7, 2022; 28(21): 2251-2281
Published online Jun 7, 2022. doi: 10.3748/wjg.v28.i21.2251
Published online Jun 7, 2022. doi: 10.3748/wjg.v28.i21.2251
HBx related pathways |
DNA repair impairment and DNA instability |
HBx - binds to DDB1 - instability of Scm5/6 - impairment in DNA replication and repair |
HBx - interacts with TFIIH - impairment in DNA replication and repair |
HBx - blocks BER pathway - impairment in DNA repair |
HBx - binds to CRM1 and sequestering it in cytoplasm - aberrant centrosome duplication and chromatin’s segregation - chromosome instability |
DNA replication increase |
HBx - upregulates RLF and CDT1 and downregulates geminin - DNA replication |
HBx - binds to cccDNA - recruiting PCAF - histone H3 acetylation - inhibition of chromatin’s methylation - DNA replication |
Cell cycle deregulation via signal pathways |
HBx - binds to p53 - impaired function of p53 - cell cycle dysregulation |
HBx - induces AFP expression - activation of PTEN and PI3K/mTOR pathway - cell cycle deregulation |
HBx - activates Notch1 and Notch4 receptor - cell cycle progression |
HBx - upregulates NF-kB, AP-1, AP-2, c-EBP, RNA-polymerase, ATF - altered oncogenes expression and cell cycle deregulation |
HBx - upregulates NF-kB - upregulation of EGR1 - upregulation of miR-3928v - downregulation of VDAC3 - tumor suppressor inhibition |
HBx - downregulates SFRP1 and SFRP5 - DNMT1 recruitment - inhibition of WNT/β-catenin pathway - epithelial mesenchymal transition |
Epigenetic modification impairment |
HBx - interacts with MBD2 and CBP - P3 and P4 promoters’ activation through hypomethylation - recruitment of IGF2 - oncogenesis |
HBx - stimulates deacetylation of IGFBP3 gene - upregulation of IGF1 - mitogenic and anti-apoptotic effects |
HBx - upregulates DNMT1 - hypermethylation of RASSF1A - tumor suppressor inhibition |
HBx - downregulates DNMT3a/DNMT3L and recruits HDAC1 - hypomethylation of oncogenes promoters including JAK/STAT3 - impairment in cell differentiation |
HBx - downregulates CD82, MTA1, PCDH10 through hypermethylation - tumor progression |
HBx - inhibits CDH1 through deacetylation - E-cadherin upregulation - metastasis promotion |
Apoptosis impairment |
HBx - upregulates Bcl2 and Mcl1, inhibits Bax - apoptosis inhibition |
HBx - upregulates Foxo4 - increased resistance to ROS damage, avoiding cell death and apoptosis |
HBx - upregulates NF-kB - increase of DR5 - TRAIL induced apoptosis |
HBx - inhibits caspase-8 inhibitor A 20 - TRAIL induced apoptosis |
mi/lnc RNA related pathways |
HBx - impairs miRNA regulation and synthesis - cell cycle deregulation |
HBx - impairs lncRNA regulation and synthesis - cell cycle deregulation |
Oxidative stress |
HBx - downregulates NQO1 - mitochondrial injury - ROS production |
C-terminal truncated HBx - mitochondrial DNA damage - ROS production |
Neoangiogenesis |
HBx - upregulates VEGF, HIF1 and ANG2 - neoangiogenesis |
Unknown mechanism |
HBx - binds to HSP60 and HSP70 - unknown function but involved in HCC carcinogenesis |
Pre-S/S related pathways |
pre-S2 - retention of HBV proteins in ER - ROS increase - cell DNA damages |
pre-S2 - retention of HBV proteins in ER - upregulation of CCNA - chromosome instability and centrosome overduplication |
pre-S2 - interacts with JAB1 - RB tumor suppressor inhibition |
HBsAg related pathways |
HBsAg - binds to ECHS1 - ROS increase - cell DNA damages |
HBsAg - binds to JTB - decreased apoptosis and increased cell mobility |
HBeAg related pathways |
HBeAg - stimulates upregulation of miR-106b - RB tumor suppressor inhibition |
HBV DNA related pathways |
cccDNA - triggers DNA repair pathways - histone degradation and cell cycle checkpoints activation - enhanced DNA recombination rate |
HBV DNA - genome integration - oncogene activation or tumor suppressor inhibition with evidence of fusion proteins |
HBV DNA - genome integration - genetic instability - clonal proliferation |
Inflammatory pathways |
Increased cytokines production (TGF-β, IL-4, IL-10, IL-12, IL-13) - JAK/STAT3 activation - cell proliferation |
CD4+ T follicular helper decrease - loss of growth inhibition and death control of cancer cells |
CD8+ cell dysfunction - impaired growth inhibition and death control of cancer cells |
Functional exhausted CD8+TIM-3+ T cells - increased viral replication - increased viral factors in HCC development |
NK cells - increase in IL-4 and IL-13 - activation of HSCs - increased cytokines production - cell cycle deregulation |
NK cells - miR-146a increase - reduced cytotoxicity and decreased IFN-γ production - reduction in immunosurveillance |
Tregs - PD1 and CTLA4 overexpression - C |
Gut microbiota-related pathways |
HBV related dysbiosis - circulating LPS - TLR4 activation - cytokines production - JAK/STAT3 activation - cell proliferation |
- Citation: Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol 2022; 28(21): 2251-2281
- URL: https://www.wjgnet.com/1007-9327/full/v28/i21/2251.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i21.2251